Ozempic maker Novo Nordisk has filed lawsuits in federal courts across the U.S., accusing several medical spas, weight-loss clinics and wellness clinics of false advertising, trademark infringement and unfair competition, alleging they illegally said they were selling custom-made versions of Ozempic and other company medicines, The Wall Street Journal’s Sara Ashley O’Brien reports. The company has asked the courts to prevent the spas and clinics from claiming their drugs contain the main ingredient in Ozempic and related drugs and to require them to disclose their products aren’t affiliated with Novo Nordisk’s and are unapproved drugs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVO:
- Novo Nordisk Takes Legal Route to Crack Down on Copycat Drugs
- Novo Nordisk price target raised to DKK 1,150 from DKK 950 at Berenberg
- Cantor Fitzgerald biotech/biopharma to hold analyst/industry conference call
- Cantor Fitzgerald biotech/biopharma to hold a luncheon meeting
- Eli Lilly price target raised to $500 from $375 at Berenberg